Announcement • Jul 16
Splash Beverage Group Inc Announces Board Approval of Reverse Stock Split Intended to Support Compliance with NYSE American's Minimum Share Price Requirements Splash Beverage Group, Inc. announced two significant actions designed to strengthen the Company's financial position and advance its previously announced NYSE American compliance plan. The Company's Board of Directors has approved a 1-for-4 reverse stock split of the Company's issued and outstanding common stock. The reverse stock split is intended to support the Company's continued compliance with NYSE American's minimum share price requirements and forms an important component of the Company's previously announced Exchange-approved compliance plan. The reverse stock split will be effective after the market closes on July 24, 2026 following the filing and effectiveness of an amendment to the Company's articles of incorporation, with the common stock trading on a post-split basis when the market opens on July 27, 2026. The reverse stock split is intended to support the Company's continued compliance with NYSE American's minimum share price requirements and is a key component of the Company's previously announced compliance plan accepted by the Exchange. The Company's common stock will continue trading on the NYSE American. Announcement • Jul 09
Splash Beverage Group, Inc. Receives Notice From NYSE Regulation And Announces Compliance Plan Acceptance On July 8, 2026, Splash Beverage Group, Inc. received notice from NYSE Regulation (the NYSE) that the NYSE has determined to accept the Company's plan to regain compliance with the NYSE American's shareholders' equity requirement as outlined in Section 1003(a)(i), (ii), and (iii) of the Company Guide (the Compliance Plan), which the Company submitted to the NYSE on May 29, 2026. Pursuant to the Compliance Plan, the Company has until January 29, 2027 to regain compliance with the continued listing standards of the NYSE American. The foregoing has no immediate impact on the listing of the Company's shares of common stock on the NYSE American. The Company's common stock will continue to be listed and traded on the NYSE American under the ticker SBEV during the period allotted for the Company to regain compliance, subject to the Company's compliance with the other continued listing standards of the NYSE American. The Company is committed to regaining compliance with the NYSE American's continued listing standards. However, there can be no assurance that the Company will ultimately regain compliance with all applicable continued listing standards within the allotted compliance period or that developments and events occurring subsequent to the date of the Compliance Plan or NYSE's approval thereof will not adversely affect the Company's ability to make sufficient progress with the Compliance Plan, regain compliance with all applicable continued listing standards, or maintain compliance with other NYSE American continued listing standards. If the Company does not regain compliance by January 29, 2027, or does not make progress consistent with its Compliance Plan during the plan period, the NYSE American may initiate delisting proceedings. Live News • Jul 07
Splash Beverage Group Secures Global Rights to CannEpil Epilepsy Therapy in Pharma Expansion Splash Beverage Group has entered into an exclusive global licensing agreement with Argent BioPharma for CannEpil®, a cannabinoid-based investigational therapy for drug-resistant epilepsy that already has patient access in several European countries and FDA engagement for U.S. development.
The deal takes Splash Beverage Group beyond beverages and into pharmaceutical therapeutics, with the company aiming to build a differentiated cannabinoid therapeutics platform and advance clinical development and commercialization of CannEpil®.
Splash Beverage Group shares last traded at $0.21, with the stock down 71.9% year to date, highlighting that this pivot into therapeutics comes against a backdrop of recent share price weakness.
This move introduces new opportunity and new risk, as investors now have to weigh drug development timelines, regulatory milestones and capital needs alongside the company’s existing beverage operations.